Claims for Patent: 10,456,420
✉ Email this page to a colleague
Summary for Patent: 10,456,420
Title: | Genetically modified NK-92 cells and monoclonal antibodies for the treatment of cancer |
Abstract: | This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor. |
Inventor(s): | Lee; Tien (Culver City, CA), Klingemann; Hans G. (Culver City, CA), Simon; Barry J. (Culver City, CA), Boissel; Laurent (Culver City, CA) |
Assignee: | NantKwest, Inc. (San Diego, CA) |
Application Number: | 15/529,848 |
Patent Claims: | 1. A method for treating cancer in a subject in need thereof comprising administering to the subject a monoclonal antibody having a cytotoxic effect and genetically modified
NK-92 cells, wherein the genetically modified NK-92 cells are genetically modified using a plasmid expression vector to generate stable NK-92 cells that express a CD16 polypeptide having a valine at position 158 of the mature form of the CD16
polypeptide; and express interleukin-2 (IL-2) targeted to the endoplasmic reticulum (ER); and further, wherein the expression vector comprises a transgene encoding the CD16 polypeptide and the IL-2 targeted to the ER comprising, in the 5' to 3'
direction: a polynucleotide encoding the CD16 polypeptide, an IRES, and a polynucleotide encoding the IL-2 targeted to the ER.
2. The method of claim 1, wherein the CD16 polypeptide comprises a polynucleotide sequence encoding a polypeptide having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:2 and comprises valine at position 158. 3. The method of claim 1, wherein the CD16 polypeptide comprises the amino acid sequence of SEQ ID NO:2. 4. The method of claim 1, wherein the genetically modified NK-92 cells are further modified to express a suicide gene. 5. The method of claim 4, wherein the suicide gene is inducible caspase 9. 6. The method of claim 1, wherein the cancer is multiple myeloma, leukemia, non-Hodgkin's lymphoma, metastatic breast cancer or gastric carcinoma. 7. The method of claim 1, wherein the monoclonal antibody is a naked monoclonal antibody of an IgG subtype that induces ADCC. 8. The method of claim 7, wherein the monoclonal antibody is alemtuzumab, rituximab, trastuzumab, avelumab, daratumumab or elotuzumab. 9. The method of claim 1, wherein the monoclonal antibody and the genetically modified NK-92 cells are administered simultaneously to the subject; or the subject is administered the monoclonal antibody and subsequently treated with the genetically modified NK-92 cells. 10. The method of claim 9, wherein the monoclonal antibody is injected intravenously into the subject. 11. The method of claim 9, wherein the genetically modified NK-92 cells are injected into the bone marrow. |
Details for Patent 10,456,420
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2035-03-27 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-03-27 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-03-27 |
Genzyme Corporation | CAMPATH | alemtuzumab | Injection | 103948 | 05/07/2001 | ⤷ Try a Trial | 2035-03-27 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.